InvestorPlace - Stock Market News, Stock Advice & Trading Tips Moderna (MRNA) stock has shed roughly 90% of its value since its 2021 peak.

A few years ago, investors rushed to buy Moderna (NASDAQ: MRNA) stock. The biotech company had brought its coronavirus vaccine to market in less than a year and quickly saw earnings take off. The ...

The deal would provide ‘certainty’ for Moderna’s vaccine portfolio.

Within the first week of 2026, the S&P 500 leaderboard has already delivered a surprise. Moderna Inc (NASDAQ: MRNA) has quietly muscled its way into the top year-to-date performers, up more than 20% ...

Including the settlement payment, Moderna now expects to end 2026 with between $4.5 billion and $5 billion in cash and cash ...

Shares of Moderna MRNA rose 13% in the past week after the company announced preliminary sales for the full-year 2025, as well as business outlook for 2026 and beyond. It also outlined some expected ...

Moderna shares surged 16% Wednesday to their highest level since 2024 after the company agreed to pay up to $2.25 billion to two other biotechnology companies to [settle patent litigation]( ...

Moderna (NASDAQ: MRNA) soared into the spotlight during the pandemic thanks to its mRNA technology and its rapid development of a coronavirus vaccine. But it's those two elements that have weighed on ...

Piper Sandler expects Moderna to generate $2.07 billion in product sales in 2026, driven largely by its next‑generation COVID vaccine, mNEXSPIKE, according to Investing.com. The FDA is set to review ...

Moderna Inc MRNA shares are rising in Tuesday’s after-hours session after the company announced it reached a settlement agreement with Arbutus Biopharma and Genevant Sciences. Moderna shares are ...

CHONGQING, CHINA - FEBRUARY 3: In this photo illustration, a smartphone displays the logo of Moderna, Inc. (NASDAQ: MRNA), a U.S.-based biotechnology company specializing in messenger RNA (mRNA) ...

Moderna is working to build a seasonal vaccines portfolio to spur growth. The FDA this week said it won’t review the biotech’s flu vaccine candidate. 10 stocks we like better than Moderna › A few ...